{"title":"非酒精性脂肪肝患者高甘油三酯水平的评估","authors":"D. Rao, V. Praveena, B. Veeranna","doi":"10.9734/ijbcrr/2017/33499","DOIUrl":null,"url":null,"abstract":"Non-alcoholic fatty liver disease (NAFLD) is starting as accumulation of fat in the hepatocytes (steatosis) which is a sub-clinical condition in those who are not consuming alcohol. Non-alcoholic steatohepatitis (NASH) is a condition of steatosis, associated with inflammation of liver cell. This is a clinical form of NAFLD, which is regarded as a major cause of cirrhosis of the liver [1]. This distinction between simple steatosis and NASH is important because the natural history of these categories differs substantially. Patients with simple steatosis usually have a benign prognosis from the point of view of liver disease [2-5]. In contrast, up to 20% of patients with NASH may ultimately develop advanced liver disease [2,4-6]. The prognosis of NASH-related cirrhosis is poor: It results in liver failure or liver-related death in approximately one third of cases [7,8]. Hepatocellular cancer is also a recently recognized complication of NASH-related cirrhosis [7,9].","PeriodicalId":13942,"journal":{"name":"International Journal of Biochemistry Research and Review","volume":"80 1","pages":"1-5"},"PeriodicalIF":0.0000,"publicationDate":"2018-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of High Levels of Triglycerides in Non-alcoholic Fatty Liver Disease\",\"authors\":\"D. Rao, V. Praveena, B. Veeranna\",\"doi\":\"10.9734/ijbcrr/2017/33499\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Non-alcoholic fatty liver disease (NAFLD) is starting as accumulation of fat in the hepatocytes (steatosis) which is a sub-clinical condition in those who are not consuming alcohol. Non-alcoholic steatohepatitis (NASH) is a condition of steatosis, associated with inflammation of liver cell. This is a clinical form of NAFLD, which is regarded as a major cause of cirrhosis of the liver [1]. This distinction between simple steatosis and NASH is important because the natural history of these categories differs substantially. Patients with simple steatosis usually have a benign prognosis from the point of view of liver disease [2-5]. In contrast, up to 20% of patients with NASH may ultimately develop advanced liver disease [2,4-6]. The prognosis of NASH-related cirrhosis is poor: It results in liver failure or liver-related death in approximately one third of cases [7,8]. Hepatocellular cancer is also a recently recognized complication of NASH-related cirrhosis [7,9].\",\"PeriodicalId\":13942,\"journal\":{\"name\":\"International Journal of Biochemistry Research and Review\",\"volume\":\"80 1\",\"pages\":\"1-5\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-02-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Biochemistry Research and Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.9734/ijbcrr/2017/33499\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Biochemistry Research and Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9734/ijbcrr/2017/33499","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Evaluation of High Levels of Triglycerides in Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is starting as accumulation of fat in the hepatocytes (steatosis) which is a sub-clinical condition in those who are not consuming alcohol. Non-alcoholic steatohepatitis (NASH) is a condition of steatosis, associated with inflammation of liver cell. This is a clinical form of NAFLD, which is regarded as a major cause of cirrhosis of the liver [1]. This distinction between simple steatosis and NASH is important because the natural history of these categories differs substantially. Patients with simple steatosis usually have a benign prognosis from the point of view of liver disease [2-5]. In contrast, up to 20% of patients with NASH may ultimately develop advanced liver disease [2,4-6]. The prognosis of NASH-related cirrhosis is poor: It results in liver failure or liver-related death in approximately one third of cases [7,8]. Hepatocellular cancer is also a recently recognized complication of NASH-related cirrhosis [7,9].